Study of GDX012 in Patients With MRD Positive AML

Clinical trial NCT05001451 · TERMINATED

Trial details

NCT number: NCT05001451
Sponsor: GammaDelta Therapeutics Limited
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2021-08-13
Primary completion: 2022-06-03
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.